Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $11
J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $10
Sector Update: Health Care Stocks Higher Friday Afternoon
12 Health Care Stocks Moving In Friday's Intraday Session
Adaptive Biotechnologies Is Maintained at Buy by Goldman Sachs
Adaptive Biotechnologies Price Target Raised to $10.00/Share From $9.00 by Goldman Sachs
Adaptive Biotechnologies Analyst Ratings
Adaptive Biotechnologies Shares Surge After Q1 Loss Narrows, Revenue Rises
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Adaptive Biotechnologies Shares Are Trading Higher After the Company Reported Q1 Financial Results and Beat Its EPS and Revenue Estimates.
William Blair Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $13
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $11
Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Adaptive Biotechnologies (ADPT)
Positive Outlook for Adaptive Biotechnologies: Strong Revenue Growth and Strategic Initiatives Support Buy Rating
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), CVS Health (CVS) and Cytokinetics (CYTK)
Express News | Adaptive Biotechnologies Corp : JP Morgan Raises Target Price to $10 From $9
Earnings Call Summary | Adaptive Biotechnologies(ADPT.US) Q1 2025 Earnings Conference
Adaptive Biotechnologies Targets 30% MRD Volume Growth in 2025 With Raised Guidance